BioPharma leaders call for gender diversity
European Pharmaceutical Review | January 12, 2017
Now that it’s 2017, we are choosing to write this letter to provide recommendations for best practices to establish gender diversity as a priority for the biopharma industry. Last year’s open letter to the industry sparked a dialogue that led to changes in some company practices, new training programs, regional gender diversity initiatives and much more. But we believe this is just the start of the work to be done.